Monday, October 11, 2021 2:41:22 PM
ZZ. I was just looking for accurate scripts numbers . Reported by Symphony and usually available to anyone with the right Bloomberg acc.
Poster Raf on the AMRN board posts these numbers for Vascepa scripts ...as an example ...which are great for those trying to estimate what the next earnings report might look like .
I'm not short AUPH ...I have a small long position
I'm waiting for the final AURORA -2 data before adding or selling .
My wife is a Nephrology PA and has patients with LN. They want to make sure there is no drop off in Kidney function ...eGFR ...before deciding how widely to prescribe, assuming insurance coverage
The AURORA-2 data will give them the full 36 mth data ..and should be available near term ( between now and EOY )
My other caution with this stock is the small % of insider and institutional ownership .
With a large % of retail ownership , this stock can be easily manipulated by hedge funds
Kiwi
Poster Raf on the AMRN board posts these numbers for Vascepa scripts ...as an example ...which are great for those trying to estimate what the next earnings report might look like .
I'm not short AUPH ...I have a small long position
I'm waiting for the final AURORA -2 data before adding or selling .
My wife is a Nephrology PA and has patients with LN. They want to make sure there is no drop off in Kidney function ...eGFR ...before deciding how widely to prescribe, assuming insurance coverage
The AURORA-2 data will give them the full 36 mth data ..and should be available near term ( between now and EOY )
My other caution with this stock is the small % of insider and institutional ownership .
With a large % of retail ownership , this stock can be easily manipulated by hedge funds
Kiwi
Recent AUPH News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 09:05:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 09:04:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 09:03:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/11/2026 08:10:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/11/2026 08:07:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 01:20:50 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 05/11/2026 01:15:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 12:23:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 12:22:07 PM
- Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress • Business Wire • 05/07/2026 12:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/21/2026 08:31:08 PM
- Form SC TO-T - Tender offer statement by Third Party • Edgar (US Regulatory) • 04/13/2026 11:27:23 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 08:56:49 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:19:38 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:19:18 PM
- Kezar Life Sciences shares surge after Aurinia announces acquisition • IH Market News • 03/30/2026 03:07:34 PM
- Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right • Business Wire • 03/30/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 12:03:47 PM
- Aurinia Announces Management Transition • Business Wire • 03/23/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 08:25:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:14:36 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 11:06:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 11:02:50 AM
- Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress • Business Wire • 02/26/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2026 09:08:05 PM
